企業プロフィール
Pacira BioSciences 株価・ニュース・カタリスト
- ティッカー:
- PCRX
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
23.24 USD (+1.04%)
終値
最終更新: 2026年8月17日
875M USD
時価総額
株価変動の要因
As of Aug 17, 2026, PCRX closed up 1.04% at $23.24. No new same-company headline was identified in the current news window.
企業概要
Non-Opioid Pain Management
Pacira BioSciences develops and commercializes non-opioid therapies for postsurgical and musculoskeletal pain. Its portfolio combines extended-release pharmaceuticals, a cryoanalgesia device and a locally administered gene-therapy program.
EXPAREL
EXPAREL is a multivesicular-liposome formulation of bupivacaine that provides prolonged local or regional analgesia after surgery. It is approved for infiltration and selected nerve blocks and anchors Pacira’s commercial franchise.
ZILRETTA
ZILRETTA is an extended-release intra-articular corticosteroid approved for osteoarthritis knee pain. A completed-enrollment Phase 3 study is evaluating expansion into osteoarthritis pain of the shoulder.
Iovera
Iovera is a handheld device that applies controlled cold temperatures to targeted nerves for immediate, drug-free pain relief. Pacira is also pursuing a registrational indication in spasticity.
PCRX-201
PCRX-201, or enekinragene inzadenovec, is a locally administered gene therapy in Phase 2 development for knee osteoarthritis. It uses a high-capacity adenoviral platform intended to drive local therapeutic protein expression with commercially viable manufacturing.
今後のカタリスト
- Part A Phase 2 data for PCRX-201 in knee osteoarthritis expected in 2026.
- Topline results from the Phase 3 ZILRETTA shoulder-osteoarthritis study expected by year-end 2026.
- Registrational iovera spasticity-study results expected in 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。